Quarterly report pursuant to Section 13 or 15(d)

Summary of the Net Purchase Price and Allocation to the Acquired Assets (Detail)

v3.19.1
Summary of the Net Purchase Price and Allocation to the Acquired Assets (Detail) - ProstaGene, LLC
9 Months Ended
Feb. 28, 2019
USD ($)
Business Acquisition, Contingent Consideration [Line Items]  
CytoDyn Inc. Equity $ 11,558,000
Acquisition Expenses 741,297
Release of Deferred Tax Asset 2,826,919
Total Cost of Acquisition 15,126,216
Intangible assets 15,126,216
Other 0
Allocation of Acquisition Costs $ 15,126,216